Literature DB >> 26751031

Identification of Invasive Salmonella Enterica Serovar Typhimurium ST313 in Ambulatory HIV-Infected Adults in Mozambique.

Troy D Moon1, Monika Johnson2, Monique A Foster2, Wilson P Silva3, Manuel Buene4, Emilio Valverde5, Luís Morais4, John V Williams6, Sten H Vermund1, Paula E Brentlinger4.   

Abstract

INTRODUCTION: Despite evidence describing the burden of invasive non-typhoidal salmonella (iNTS) disease in sub-Saharan Africa, iNTS is not recognized as a priority within global health policy institutions. Recently, Salmonella enterica serovar Typhimurium, sequence type (ST) 313, has been identified as the predominant cause of iNTS disease in multiple sub-Saharan African countries.
MATERIALS AND METHODS: We conducted multilocus sequence typing (MLST) to determine the prevalence of the ST313 genotype in a sample of blood isolates from ambulatory HIV-infected Mozambican adults with iNTS disease.
RESULTS: Of the 29 samples of NTS obtained and analyzed by MLST, all (29/29) were assigned the ST313 sequence type based on the set of allele types derived from each of the seven loci. For quality control, five randomly selected strains taken from the original cultures were confirmed as ST313, and the positive control strain SL3261 (taken from the original culture) was categorized as S. Typhimurium ST19.
CONCLUSION: S. Typhimurium ST313 is an important example of a widely distributed pathogen that lacks a coordinated strategy for control. The highly vulnerable populations at risk for ST313 infection in Mozambique, and within the region, would benefit greatly from the development of new policy and on-the-ground capacity to support increased surveillance, prevention, and treatment initiatives.

Entities:  

Keywords:  Africa; Human immunodeficiency virus; Invasive non-typhoidal salmonella; Salmonella Typhimurium ST313

Year:  2015        PMID: 26751031      PMCID: PMC4693304          DOI: 10.4103/0974-777X.170496

Source DB:  PubMed          Journal:  J Glob Infect Dis        ISSN: 0974-777X


INTRODUCTION

During the 20th century, nontyphoidal Salmonella (NTS) — previously associated primarily with localized gastrointestinal infections that often resolved without antibiotic treatment — evolved into an important cause of invasive and often fatal bacterial infections within specific subregions of sub-Saharan Africa. Invasive NTS (iNTS) disease most commonly affects immunosuppressed populations (young, human immunodeficiency virus (HIV)-infected, malnourished) and those with other specific comorbidities (especially malaria and anemia).[123] In parallel with NTS's evolution from a less-invasive to invasive pathogen, certain subtypes have become resistant to most first-line antibiotics in common use in Africa,[45] and the mode of transmission may be evolving from foodborne/zoonotic to person-to-person.[6] Recently, Salmonella enterica serovar Typhimurium, sequence type (ST) 313, has been identified as the predominant cause of iNTS disease in multiple sub-Saharan African countries, although other NTS strains have also been implicated. In an analysis of 129 specimens obtained from patients with invasive Salmonella typhimurium (S. typhimurium) in seven sub-Saharan African nations between 1988 and 2010, 120 (93.0%) were identified as ST313.[7] This recent evolution in the characteristics and behavior of sub-Saharan African NTS strains has important implications for clinical and public health policy. Clinically, iNTS disease is difficult to distinguish from malaria and other bacterial bloodstream infections without recourse to blood cultures and other diagnostics that are often unavailable in the region. Because conventional first-line antibiotics are commonly ineffective and mortality rates are high in iNTS disease, countries lacking relevant diagnostic capacity must choose between overuse of expensive second- and third-line antimicrobials or undertreatment of iNTS infection. As there is yet no effective vaccine for NTS, uncertainty about the importance of person-to-person vs foodborne or zoonotic transmission also creates doubt about effective selection of prevention interventions. We recently reported that multidrug resistant S. typhimurium was the predominant pathogen associated with bacteremia in febrile HIV-infected adults in Zambézia Province, Mozambique.[8] Multidrug resistant NTS has been shown to be an important and often lethal cause of bloodstream infection in Mozambican children of unknown HIV serostatus.[910] The ST313 genotype was identified in 11 of 12 NTS isolates acquired from Mozambican adults of unknown HIV serostatus between 2001 and 2004.[7] We hypothesized that ST313 might be represented among iNTS isolates acquired from our study subjects. Therefore, we performed further investigation to characterize the Zambézian isolates genetically.

MATERIALS AND METHODS

We conducted a prospective observational study between May and September, 2012 (NCT 01681914, www.clinicaltrials.gov), at three health centers in Zambézia Province, Mozambique, to evaluate the performance of new Mozambican guidelines for non-physician clinician management of fever (or history of fever) in HIV-infected adults (previously described).[811] At enrollment, bacterial blood cultures were collected from all eligible subjects. Briefly, 39 (15.1%) of 258 study subjects had blood-culture confirmed bacteremia. One subject had blood-culture confirmed bacteremia on two separate occasions. Thirty-two of 40 isolates (80%) were identified as NTS. We excluded the second specimen for the subject with two positive cultures. Based on serotyping (the only assay available in the field), 27 of the remaining 39 (69.2%) isolates were identified as S. typhimurium, nearly all resistant to multiple first-line antibiotics (ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole), one was identified as S. enteritidis, two as Salmonella Group O:4, and one as Salmonella spp.[8] We conducted multilocus sequence typing (MLST) to determine the prevalence of the ST313 genotype in our 27 S. typhimurium isolates.[12] Additionally, we conducted MLST on one of the Salmonella Group O:4 isolates and the Salmonella spp. isolate. The second Salmonella Group O:4 was not tested due to contamination found at shipping. The S. enteritidis isolate was excluded from analysis. Deoxyribonucleic acid (DNA) was extracted according to a protocol adapted from Stepan et al.,[13] Salmonella isolates were streaked onto Salmonella/Shigella (SS) agar and incubated at 37°C for 18 h. Colonies were resuspended in 40 mL of Proteinase K (Roche Diagnostics) and lysed at 80°C for 10 min, then 55°C for 10 min on a C1000 Touch™ (Bio-Rad) or a PTC-200 (MJ Research) thermocycler. Following incubation, 40 mL of sterile nuclease-free water were added, and the suspension was centrifuged at 10,000g for 1 min. The supernatant containing DNA was transferred to a sterile tube and stored at 4°C until further use. Seven housekeeping genes (aroC, dnaN, hemD, hisD, purE, sucA, and thrA) were amplified using the recommended primer pairs listed on the University of Warwick's MLST website (http://mlst.warwick.ac.uk/mlst/dbs/Senterica/documents/primersEnterica_html). Polymerase chain reaction (PCR) testing was performed in 40 mL reaction mixtures containing 1 U HotStarTaq® DNA polymerase (Qiagen), 1 × PCR buffer, 1.5 mM MgCl2, 200 mM of each dNTP, 0.4 mM each of forward and reverse primer (Sigma), and 2 mL of extracted DNA on a PTC-200. Cycling conditions consisted of an initial activation at 95°C for 15 min and 35 cycles of 30 s at 94°C, 45 s at 55°C, and 1 min at 72°C, followed by a final extension at 72°C for 10 min. PCR products were diluted to 100 ng/mL and submitted to Vanderbilt Technologies for Advanced Genomics (VANTAGE) for sequencing. Samples were purified with ExoSAP-IT (Affymetrix) and sequenced in both directions with the appropriate forward and reverse primers on an ABI 3730 × l DNA analyzer (Life Technologies). PeakTrace basecaller (Nucleics) was used to process trace data and designate bases. If forward and reverse sequences for a specimen were discordant, the specimen was resequenced. Sequence data were imported into MacVector 12.0 (MacVector, Inc.), trimmed, aligned, and compared to control sequences obtained from the MLST Warwick site (http://mlst.warwick.ac.uk/mlst/dbs/Senterica/Downloads_HTML). Sequence types for the Salmonella isolates were determined by using the Allele/ST Query tool of the Salmonella enterica MLST Database (http://mlst.warwick.ac.uk/mlst/dbs/Senterica/). For quality control, we also streaked five randomly selected strains and the positive control strain S. typhimurium SL3261 onto SS agar from original cultures, extracted, and amplified as described above.

Ethics

The Mozambican National Committee for Bioethics in Health and the Vanderbilt University Institutional Review Board had both approved the parent study and subsequently granted additional approval for the de-identified specimens to be sent to Vanderbilt University for MLST, a technique not then available in Mozambique.

RESULTS

Of the 29 samples of NTS obtained and analyzed by MLST, all (29/29) were assigned the ST313 sequence type based on the set of allele types derived from each of the seven loci [Table 1]. The five randomly selected strains taken from the original cultures were confirmed as ST313, and the positive control strain SL3261 (taken from the original culture) was categorized as S. typhimurium ST19.
Table 1

Genetic characterization of Salmonella enterica serovar S. typhimurium

Genetic characterization of Salmonella enterica serovar S. typhimurium

DISCUSSION

In our study, MLST analysis confirmed the presence of the highly invasive S. typhimurium ST313 in febrile HIV-infected adults in Mozambique, and showed genotypic homogeneity among all isolates of this multidrug resistant S. Typhimurium. ST313 was the only sequence type identified, and the predominant cause of bacteremia, in our subjects. We believe that the finding of 100% ST313 is plausible because other studies conducted in sub-Saharan Africa have found ST313 prevalence of over 95% among invasive S. typhimurium isolates.[714] For example, in Malawi, which shares a border with Zambézia Province, ST313 represented 56/58 (96.6%) of isolates obtained from blood and cerebrospinal fluid.[7] Because all of our specimens were derived from febrile, HIV-infected adults in three closely-approximated districts in a single province in Mozambique during one 5-month period, our results may not be generalizable either to other HIV-infected populations within Mozambique or to other immunocompromised Mozambican groups, such as severely malnourished children. However, our findings confirm that ST313 has persisted in Mozambique, where its presence was previously documented in samples acquired over a decade ago,[7] and that it now represents an important threat to the survival of HIV-infected Mozambican adults. In December 2014, both the World Health Organization and the Review on Antimicrobial Resistance issued calls for implementation of new worldwide initiatives for control of antimicrobial resistance, because of the associated and growing burdens of mortality, morbidity, and negative economic consequences.[1516] S. typhimurium ST313 is an important example of a widely distributed pathogen that lacks a coordinated strategy for control. The highly vulnerable populations at risk for ST313 infection in Mozambique, and within the region, would benefit greatly from the development of new policy and on-the-ground capacity to support increased surveillance, prevention, and treatment initiatives, with particular attention to the needs of HIV-infected, malnourished, and other groups characterized by increased susceptibility to this often-fatal infection.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  14 in total

1.  Management of fever in ambulatory HIV-infected adults in resource-limited settings: prospective observational evaluation of a new Mozambican guideline.

Authors:  Paula E Brentlinger; Wilson P Silva; Manuel Buene; Luis Morais; Emilio Valverde; Sten H Vermund; Troy D Moon
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

2.  Invasive multidrug-resistant non-typhoidal Salmonella infections in Africa: zoonotic or anthroponotic transmission?

Authors:  Samuel Kariuki; Gunturu Revathi; Nyambura Kariuki; John Kiiru; Joyce Mwituria; Jane Muyodi; Jane W Githinji; Dorothy Kagendo; Agnes Munyalo; C Anthony Hart
Journal:  J Med Microbiol       Date:  2006-05       Impact factor: 2.472

3.  Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi.

Authors:  Melita A Gordon; Stephen M Graham; Amanda L Walsh; Lorna Wilson; Amos Phiri; Elizabeth Molyneux; Eduard E Zijlstra; Robert S Heyderman; C Anthony Hart; Malcolm E Molyneux
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

4.  Salmonella bacteremia in Kenyan children.

Authors:  Andrew J Brent; Joe O Oundo; Isaiah Mwangi; Lucy Ochola; Brett Lowe; James A Berkley
Journal:  Pediatr Infect Dis J       Date:  2006-03       Impact factor: 2.129

5.  Antimicrobial susceptibility and mechanisms of resistance in Shigella and Salmonella isolates from children under five years of age with diarrhea in rural Mozambique.

Authors:  Inácio Mandomando; Dinis Jaintilal; Maria J Pons; Xavier Vallès; Mateu Espasa; Laura Mensa; Betuel Sigaúque; Sergi Sanz; Jahit Sacarlal; Eusébio Macete; Fátima Abacassamo; Pedro L Alonso; Joaquim Ruiz
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

6.  Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital.

Authors:  Quique Bassat; Caterina Guinovart; Betuel Sigaúque; Inácio Mandomando; Pedro Aide; Jahit Sacarlal; Tacilta Nhampossa; Azucena Bardají; Luís Morais; Sonia Machevo; Emilio Letang; Eusébio Macete; John J Aponte; Anna Roca; Clara Menéndez; Pedro L Alonso
Journal:  Trop Med Int Health       Date:  2009-06-22       Impact factor: 2.622

7.  Molecular and comparative analysis of Salmonella enterica Senftenberg from humans and animals using PFGE, MLST and NARMS.

Authors:  Ryan M Stepan; Julie S Sherwood; Shana R Petermann; Catherine M Logue
Journal:  BMC Microbiol       Date:  2011-06-27       Impact factor: 3.605

8.  Multilocus sequence typing as a replacement for serotyping in Salmonella enterica.

Authors:  Mark Achtman; John Wain; François-Xavier Weill; Satheesh Nair; Zhemin Zhou; Vartul Sangal; Mary G Krauland; James L Hale; Heather Harbottle; Alexandra Uesbeck; Gordon Dougan; Lee H Harrison; Sylvain Brisse
Journal:  PLoS Pathog       Date:  2012-06-21       Impact factor: 6.823

Review 9.  The association between malaria and non-typhoid Salmonella bacteraemia in children in sub-Saharan Africa: a literature review.

Authors:  Ebako Ndip Takem; Anna Roca; Aubrey Cunnington
Journal:  Malar J       Date:  2014-10-13       Impact factor: 2.979

10.  Invasive Salmonella enterica serotype typhimurium infections, Democratic Republic of the Congo, 2007-2011.

Authors:  Benedikt Ley; Simon Le Hello; Octavie Lunguya; Veerle Lejon; Jean-Jacques Muyembe; François-Xavier Weill; Jan Jacobs
Journal:  Emerg Infect Dis       Date:  2014-04       Impact factor: 6.883

View more
  3 in total

1.  Multidrug-resistant Nontyphoidal Salmonella Hotspots as Targets for Vaccine Use in Management of Infections in Endemic Settings.

Authors:  Samuel Kariuki; Cecilia Mbae; Robert Onsare; Susan M Kavai; Celestine Wairimu; Ronald Ngetich; Mohammad Ali; John Clemens; Gordon Dougan
Journal:  Clin Infect Dis       Date:  2019-02-15       Impact factor: 9.079

Review 2.  Current perspectives on invasive nontyphoidal Salmonella disease.

Authors:  Andrea H Haselbeck; Ursula Panzner; Justin Im; Stephen Baker; Christian G Meyer; Florian Marks
Journal:  Curr Opin Infect Dis       Date:  2017-10       Impact factor: 4.915

3.  Antimicrobial Resistance in Endemic Enteric Infections in Kenya and the Region, and Efforts Toward Addressing the Challenges.

Authors:  Samuel Kariuki; Celestine Wairimu; Cecilia Mbae
Journal:  J Infect Dis       Date:  2021-12-20       Impact factor: 5.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.